Colibacterin (Lyophilisate) Instructions for Use

ATC Code

A07FA (Antidiarrheal microorganisms)

Clinical-Pharmacological Group

Drug regulating the balance of intestinal microflora (probiotic)

Pharmacotherapeutic Group

MIBP-eubiotic

Pharmacological Action

It exhibits antagonism against a broad spectrum of pathogenic and opportunistic microorganisms, including Shigella, Salmonella, Proteus, Staphylococcus, Klebsiella, and other species, and thereby normalizes the intestinal microflora.

The mechanism of action consists of suppressing the vital activity of pathogenic microorganisms, competitively displacing opportunistic and other non-physiological bacteria; normalizing immunological processes by enhancing the synthesis of immunoglobulins, lysozyme, interferon, activating macrophages, etc.; producing a complex of enzymes (protease, amylase, lipase, cellulase, etc.) that improve digestion; synthesizing B vitamins (B₁, B₆, B₁₂, etc.) and amino acids; binding, neutralizing, and eliminating from the body toxic products of the vital activity of putrefactive and other bacteria, products of incomplete metabolism, which provides an anti-allergic effect; improving the absorption of macro- and microelements, including iron, calcium, and phosphorus.

Indications

Dysbacteriosis of various etiologies (including during radiation cytotoxic therapy; after taking antimicrobial drugs or corticosteroids; during stress and exposure to extreme conditions); acute infectious diarrhea; diarrhea against the background of chronic diseases of the gastrointestinal tract.

ICD codes

Dosage Regimen

Lyophilisate

Orally, mixed with water (50-100 ml), natural juices, vegetable and fruit decoctions, compote, and other liquid products, 30 minutes before or 1.5 hours after meals.

For adults with acute diarrhea – 10-15 doses (2-3 dessert spoons) every 3 hours for 1-2 days, then 5-10 doses (1-2 dessert spoons) 3 times/day for 3-5 days.

For chronic diarrhea, dysbacteriosis, post-radiation colitis, chronic enterocolitis, gastrointestinal dysfunction (excessive gas formation, intestinal pain), chronic hepatitis – 5 doses (1 dessert spoon) 3 times a day for 1-3 months; for metabolic disorders, reduced immunity, after antibiotic therapy – 5 doses (1 dessert spoon) 2-3 times a day for 1-3 months.

For prevention in infection foci, as well as in the initial stages of diseases, during stress, exposure to extreme conditions – 5 doses (1 dessert spoon) 3 times/day throughout the incubation period and for another 2-3 days. In individual cases, an increase in dosage is possible.

For children under 1 year – 1-1.5 doses (from a few drops to 1/2 teaspoon) 2-3 times/day until recovery; 1-3 years – 1/4 of the adult dose; 6-10 years – 1/2 of the adult dose; from 11 years – adult dose.

If the patient has a pronounced allergic reaction, administration begins with a small amount – 1-1.5 doses (1 teaspoon) 1 time/day, and in the absence of allergic reactions, the dose is gradually increased. In rare cases, the use of the drug in the first days may increase gas formation and the associated intestinal pain. In this case, it is recommended to administer the drug via microenema, and after 1-2 weeks, switch to oral administration, starting with 1-1.5 doses (1 teaspoon) 1 time/day with its further gradual increase.

Adverse Reactions

In the first days of administration in diseases of the small intestine – flatulence and intestinal pain.

Contraindications

Hypersensitivity.

Pediatric Use

Use is possible according to the dosing regimen.

Storage Conditions

Store at 2°C (36°F) to 8°C (46°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Over-the-Counter

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.